Globus Medical Q2 EPS Forecast Boosted by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Zacks Research upped their Q2 2025 earnings estimates for shares of Globus Medical in a research note issued on Tuesday, January 21st. Zacks Research analyst R. Department now expects that the medical device company will earn $0.86 per share for the quarter, up from their prior estimate of $0.85. The consensus estimate for Globus Medical’s current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2025 earnings at $0.95 EPS and FY2026 earnings at $3.97 EPS.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.18. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The company had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. During the same period in the previous year, the company earned $0.57 EPS. The business’s quarterly revenue was up 63.1% compared to the same quarter last year.

Several other brokerages also recently weighed in on GMED. Bank of America raised Globus Medical from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $80.00 to $97.00 in a research report on Thursday, January 9th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $83.00 to $100.00 in a research report on Monday, December 2nd. Stifel Nicolaus boosted their target price on shares of Globus Medical from $80.00 to $92.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a research note on Thursday, January 9th. Finally, Truist Financial lifted their price target on shares of Globus Medical from $85.00 to $90.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and a consensus price target of $96.91.

Globus Medical Stock Performance

NYSE GMED opened at $92.42 on Wednesday. The firm has a market capitalization of $12.59 billion, a price-to-earnings ratio of 137.94, a PEG ratio of 1.76 and a beta of 1.19. Globus Medical has a one year low of $49.33 and a one year high of $93.67. The company’s 50 day moving average price is $84.64 and its 200 day moving average price is $76.45.

Institutional Investors Weigh In On Globus Medical

Hedge funds and other institutional investors have recently bought and sold shares of the business. V Square Quantitative Management LLC acquired a new stake in shares of Globus Medical during the third quarter worth $27,000. Quarry LP raised its holdings in Globus Medical by 698.4% during the 3rd quarter. Quarry LP now owns 495 shares of the medical device company’s stock worth $35,000 after buying an additional 433 shares during the period. UMB Bank n.a. raised its holdings in Globus Medical by 60.2% during the 4th quarter. UMB Bank n.a. now owns 548 shares of the medical device company’s stock worth $45,000 after buying an additional 206 shares during the period. Farther Finance Advisors LLC lifted its stake in Globus Medical by 230.5% during the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock valued at $39,000 after buying an additional 385 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Globus Medical by 40.7% in the third quarter. GAMMA Investing LLC now owns 888 shares of the medical device company’s stock worth $64,000 after buying an additional 257 shares during the period. 95.16% of the stock is currently owned by institutional investors.

Insider Activity

In related news, SVP Kelly Huller sold 5,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $81.01, for a total value of $405,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel T. Scavilla sold 60,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total transaction of $4,801,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 81,667 shares of company stock valued at $6,674,554. Insiders own 18.54% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.